NEW YORK, May 13, 2021 /PRNewswire/ -- MindMed
(NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading
psychedelic-inspired medicine company has appointed Peter Mack PhD
as Vice President of Pharmaceutical Development.
As MindMed progresses it's Discover and Develop efforts for
multiple commercial clinical programs including LSD and an ibogaine
derivative, 18-MC, Peter will lead MindMed's product development
activities across its entire portfolio of investigational drugs. In
addition, Peter will oversee partnerships with Contract
Manufacturing Development Organizations and other discovery efforts
to support the advancement of MindMed's proprietary new chemical
entities.
Peter joins MindMed from AstraZeneca, where he was the Director
of Manufacturing for Inhalation Product Development. Peter
previously worked at Pearl Therapeutics (acquired by AstraZeneca in
2013) where he helped pioneer the pharmaceutical development of
inhaled combination therapies for highly prevalent respiratory
diseases.
Peter holds a dual PhD in Medical Engineering / Medical Physics
from Harvard Medical School and
Massachusetts Institute of Technology
(MIT), where he was a National
Institute of Health (NIH) Biomechanics Training Grant
Recipient. Peter also holds a Masters of Science in
Mechanical Engineering from MIT. During his time in academia
and the pharmaceutical industry, Peter contributed to numerous peer
reviewed articles and patents.
"MindMed is constantly on the hunt to find the best people to
help us shape the future of psychedelic medicine from discovery to
delivery. We are excited to have Peter join us on our mission and
help us craft a world class pharmaceutical development
organization," said J.R. Rahn, Chief Executive Officer and
Co-founder of MindMed.
About MindMed
MindMed is a clinical-stage psychedelic medicine biotech company
that discovers, develops and deploys psychedelic inspired medicines
and therapies to address addiction and mental illness. The company
is assembling a compelling drug development pipeline of innovative
treatments based on psychedelic substances including Psilocybin,
LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed
executive team brings extensive biopharmaceutical experience to
MindMed's approach to developing the next generation of psychedelic
inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO exchange under the symbol MMED. MindMed is also traded
in Germany under the symbol
MMQ.
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute "forward-looking information" within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as "will", "may", "should", "could",
"intend", "estimate", "plan", "anticipate", "expect", "believe",
"potential" or "continue", or the negative thereof or similar
variations. Forward-looking information in this news release
include, but are not limited to, statements regarding the duration
of patent protections for NCE tryptamine and whether such
protections will extend beyond the FDA-granted NCE exclusivity
period and the impact that NCE tryptamine will have on the
Company's future pipeline. Although the Company believes that
the expectations reflected in such forward-looking information are
reasonable, such information involves risks and uncertainties, and
undue reliance should not be placed on such information, as unknown
or unpredictable factors could have material adverse effects on
future results, performance or achievements of the Company. There
are numerous risks and uncertainties that could cause actual
results and the Company's plans and objectives to differ materially
from those expressed in the forward-looking information, including
history of negative cash flows; limited operating history;
incurrence of future losses; availability of additional capital;
lack of product revenue; compliance with laws and regulations;
difficulty associated with research and development; risks
associated with clinical trials or studies; heightened regulatory
scrutiny; early stage product development; clinical trial risks;
regulatory approval processes; novelty of the psychedelic inspired
medicines industry; as well as those risk factors discussed or
referred to herein and the risks described under the headings "Risk
Factors" in the Company's filings with the securities regulatory
authorities in all provinces and territories of Canada which are available under the
Company's profile on SEDAR at www.sedar.com and with the U.S.
Securities and Exchange Commission on EDGAR at www.sec.gov.
Should one or more of these risks or uncertainties materialize, or
should assumptions underlying the forward-looking information prove
incorrect, actual results and future events could differ materially
from those anticipated in such information. Although the Company
has attempted to identify important risks, uncertainties and
factors that could cause actual results to differ materially, there
may be others that cause results not to be as anticipated,
estimated or intended. These and all subsequent written and oral
forward-looking information are based on estimates and opinions of
management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the
Company does not intend and does not assume any obligation to
update this forward-looking information.
Media Contact: mindmed@150bond.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mindmed-bolsters-management-team-appoints-peter-mack-phd-as-vice-president-of-pharmaceutical-development-301290632.html
SOURCE Mind Medicine (MindMed) Inc.